Antimicrobial resistance among gram-negative organisms in the intensive care unit

Current Opinion in Critical Care

Volumn 9, Issue 5, 2003, Pages 413-423

  Clark, Nina M ^a   Patterson, Jan ^b   Lynch III, Joseph P ^c,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Acinetobacter baumannii; Antimicrobial resistance; ESBL; Pseudomonas aeruginosa; Stenotrophomonas maltophilia

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MINOCYCLINE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULTAMICILLIN; TIMENTIN; TRIMETHOPRIM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; EMPIRICISM; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; HEALTH SURVEY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION RISK; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOMES RESEARCH; PATHOGENICITY; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SEROPREVALENCE; STENOTROPHOMONAS MALTOPHILIA; TREATMENT INDICATION; TREATMENT PLANNING;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; ENTEROBACTER; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; RISK FACTORS; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UNITED STATES;

EID: 0141673604     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200310000-00012     Document Type: Review

References (118)

1. Stephen J, Mutnick A, Jones RN: 2002. Assessment of pathogens and resistance patterns among intensive care unit patients in North America: initial report from the SENTRY Antimicrobial Surveillance Program (2001). Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy. San Diego, CA: American Society for Microbiology; Abstract C2-297.
2. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001. Am J Infect Control 2001, 29:404-421.
3. Jones RN: Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Resp Crit Care Med 2003, 24:121-134.
4. Fridkin SK, Hill HA, Volkova NV, et al.: Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002, 8:697-701.
5. Chow JW, Fine MJ, Shlaes DM, et al.: Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
6. Gentry C, Flournoy DJ, Reinert R: Analysis of antimicrobial resistance among gram-negative bacilli and antimicrobial use in intensive care unit patients for 5 years in a Veterans Affairs medical center. Am J Infect Control 2002, 30:411-416.
7. Neuhauser MM, Weinstein RA, Rydman R, et al.: Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003, 289:885-888.
8. Ballow CH, Schentag JJ: Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis 1992, 15(suppl):37S-42S.
9. Heusser MF, Patterson JE, Kuritza AP, et al.: Emergence of resistance to multiple beta-lactams in Enterobacter cloacae during treatment for neonatal meningitis with cefotaxime. Pediatr Infect Dis J 1990, 9:509-512.
10. Sanders WE Jr, Sanders CC: Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 1988, 10:830-838.
11. Patterson J: Extended-spectrum beta-lactamases. Semin Resp Crit Care Med 2003, 24:79-87. Comprehensive review of ESBLs including historical perspective, epidemiology, prevalence, risk factors, prevention, and treatment.
12. Jones RN, Biedenbach DJ, Gales AC: Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents 2003,21(1):1-7. Update of the SENTRY surveillance data from the United States (1997-2000) for Enterobacter spp and K. pneumoniae. From 1997 to 2000, Enterobacter resistance rates to aztreonam, ceftazidime, and ceftriaxone ranged from 12.3 to 21.4%. Resistance in Klebsiella ranged from 5.9 to 6.8%. Coresistanee to other antibiotic classes was common among ceftazidime-resistant isolates. The active agents (99% susceptibility) against Enterobacter spp and K. pneumoniae were carbapenems and fourth-generation cephalosporins (cefepime or cefpirome).
13. Thauvin-Eliopoulos C, Tripodi MF, Moellering RC Jr, et al.: Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997, 41:1053-1057.
14. Winokur PL, Canton R, Casellas JM, et al.: Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001, 32(suppl 2):S94-S103.
15. Meyer KS, Urban C, Eagan JA, et al.: Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993, 119:353-358.
16. Winokur P, Chenoweth C, Rice L, et al.: Resistant pathogens: emergence and control. In Ventilator-associated pneumonia. Edited by Wunderink RG, Rello J. Norwell, MA: Kluwer Academic Publishers; 2001:131-164.
17. Rahal JJ, Urban C, Horn D, et al.: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998, 280:1233-1237.
18. Lucet JC, Chevret S, Decre D, et al.: Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996, 22:430-436.
19. Monnet DL, Biddle JW, Edwards JR, et al.: Evidence of interhospital transmission of extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in the United States, 1986 to 1993. The National Nosocomial Infections Surveillance System. Infect Control Hosp Epidemiol 1997, 18:492-498.
20. Pena C, Pujol M, Ardanuy C, et al.: Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998, 42:53-58.
21. Wong-Beringer A, Hindler J, Loeloff M, et al.: Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002, 34:135-146.
22. Jacoby GA: Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. Infect Dis Clin North Am 1997, 11:875-887.
23. Martinez-Martinez L, Pascual A, Jacoby GA: Quinolone resistance from a transferable plasmid. Lancet 1998, 351:797-799.
24. Paterson DL, Ko WC, Von Gottberg A, et al.: Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001, 39:2206-2212.
25. Rice LB, Carias LL, Bonomo RA, et al.: Molecular genetics of resistance to both ceftazidime and beta-lactam-beta-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to beta-lactam therapy. J Infect Dis 1996, 173:151-158.
26. Martinez-Martinez L, Pascual A, Hernandez-Alles S, et al.: Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 1999, 43:1669-1673.
27. Paterson DL: Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000, 6:460-463.
28. Manikal VM, Landman D, Saurina G, et al.: Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000, 31:101-106.
29. Rice LB, Eckstein EC, DeVente J, et al.: Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996, 23:118-124.
30. Landman D, Chockalingam M, Quale JM: Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999, 28:1062-1066.
31. Ahmad M, Urban C, Mariano N, et al.: Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999, 29:352-355.
32. Fridkin SK, Gaynes RP: Antimicrobial resistance in intensive care units. Clin Chest Med 1999, 20:303-316, viii.
33. Gales AC, Jones RN, Turnidge J, et al.: Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32(suppl 2):S146-S155.
34. Trouillet JL, Chastre J, Vuagnat A, et al.: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998, 157:531-539.
35. Trouillet JL, Vuagnat A, Combes A, et al.: Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002, 34:1047-1054.
36. Rello J, Sa-Borges M, Correa H, et al.: Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999, 160:608-613.
37. Talon D, Mulin B, Rouget C, et al.: Risks and routes for ventilator-associated pneumonia with Pseudomonas aeruginosa. Am J Respir Crit Care Med 1998, 157:978-984.
38. Bergmans DC, Bonten MJ, van Tiel FH, et al.: Cross-colonisation with Pseudomonas aeruginosa of patients in an intensive care unit. Thorax 1998, 53:1053-1058.
39. Livermore DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002, 34:634-640.
40. Quinn JP: Pseudomonas aeruginosa infections in the intensive care unit. Semin Resp Crit Care Med 2003, 24:61-68. Comprehensive review of P. aeruginosa including microbiology, epidemiology, pathogenesis, risk factors, and emergence of resistance.
41. Harris AD, Smith D, Johnson JA, et al.: Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002, 34:340-345. A case control study evaluated risk factors for imipenem-resistant Pseudomonas aeruginosa (IRPA). Two control groups were compared. The first control group had imipenem-susceptible PA (ISPA); no PA was isolated in the second control group. Prior antibiotic use (within 14 days) was associated with isolation of both IRPA and ISPA, but different antibiotic classes were implicated. Risk factors for isolation of IRPA included prior therapy with imipenem (odds ratio [OR], 4.96; piperacillin-tazobactam [OR, 2.39]; vancomycin [OR, 1.80], and aminoglycosides [OR, 2.19]). Risk factors for isolation of ISPA included vancomycin (OR, 1.64); ampicillin/sulbactam (OR,2.00); second-generation cephalosporins (OR, 2.00). Previous stay in the ICU was a risk factor for both IRPA (OR, 3.26) and ISPA (OR, 3.53).
42. Iaconis JP, Pitkin DH, Sheikh W, et al.: Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin Infect Dis 1997, 24(suppl 2):S191-S196.
43. Sahm DF, Critchley IA, Kelly LJ, et al.: Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob Agents Chemother 2001, 45:267-274.
44. Drusano GL: Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome. J Chemother 2000, 12(suppl 4):21-26.
45. Aubert D, Poirel L, Chevalier J, et al.: Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001, 45:1615-1620.
46. Livermore DM: Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001, 47:247-250.
47. Troillet N, Samore MH, Carmeli Y: Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997, 25:1094-1098.
48. Harris A, Torres-Viera C, Venkataraman L, et al.: Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999, 28:1128-1133.
49. Carmeli Y, Troillet N, Eliopoulos GM, et al.: Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999, 43:1379-1382.
50. Acar JF, Goldstein FW: Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997, 24(suppl 1):S67-S73.
51. Fink MP, Snydman DR, Niederman MS, et al.: Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994, 38:547-557.
52. Armstrong DS, Nixon GM, Carzino R, et al.: Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002, 166:983-987.
53. Levin AS, Barone AA, Penco J, et al.: Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999, 28:1008-1011.
54. Denton M, Kerr K, Mooney L, et al.: Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002, 34:257-261.
55. Lomovskaya O, Warren MS, Lee A, et al.: Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001, 45:105-116.
56. Hammond GG, Huber JL, Greenlee ML, et al.: Inhibition of IMP-1 metallo-beta-lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives(dagger). FEMS Microbiol Lett 1999, 179:289-296.
57. Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
58. Rello J, Mariscal D, March F, et al.: Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med 1998, 157:912-916.
59. Moellering RC Jr: Antibiotic resistance: lessons for the future. Clin Infect Dis 1998, 27(suppl 1):S135-S140; discussion S141-S132.
60. El Amari EB, Chamot E, Auckenthaler R, et al.: Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001, 33:1859-1864.
61. Lynch JP 3rd: Combination antibiotic therapy is appropriate for nosocomial pneumonia in the intensive care unit. Semin Respir Infect 1993, 8:268-284.
62. Drusano GL: Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003, 36(suppl 1):S42-S50.
63. Song W, Woo HJ, Kim JS, et al.: In vitro activity of beta-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003, 21:8-12.
64. Villers D, Espaze E, Coste-Burel M, et al.: Nosocomial Acinetobacter baumannii infections: microbiological and clinical epidemiology. Ann Intern Med 1998, 129:182-189.
65. Husni RN, Goldstein LS, Arroliga AC, et al.: Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest 1999, 115:1378-1382.
66. Bergogne-Berezin E, Towner KJ: Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996, 9:148-165.
67. Cisneros JM, Reyes MJ, Pachon J, et al.: Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996, 22:1026-1032.
68. Spencer RC: Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis 1996, 15:281-285.
69. Richards MJ, Edwards JR, Culver DH, et al.: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999, 27:887-892.
70. Gales AC, Jones RN, Forward KR, et al.: Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001, 32(suppl 2):S104-S113.
71. Chastre J: Infections due to Acinetobacter baumannii in the ICU. Semin Resp Crit Care Med 2003, 24:69-78. Superb review of infections due to A. baumannii in the ICU (reviews microbiology, incidence, predisposing factors, endemicity and nosocomial infections, clinical features, and treatment.
72. Gamacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al.: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003, 36:1111-1118. Prospective study of 35 episodes of VAP due to MDR-A. baumannii. Twenty-one patients with isolates susceptible only to colistin were treated with this antimicrobial intravenously. Fourteen patients with strains susceptible to Imi-C were treated with this agent. Clinical cures were achieved in 57% in both groups. In-hospital mortality rates were high in both groups (62% with colistin; 64% with Imi-C). Colistin was well tolerated with no signs of neuromuscular blockade and insignificant nephrotoxicity.
73. Simor AE, Lee M, Vearncombe M, et al.: An outbreak due to multiresistant Acinetobacter baumannii in a burn unit: risk factors for acquisition and management. Infect Control Hosp Epidemiol 2002, 23:261-267.
74. McDonald LC, Banerjee SN, Jarvis WR: Seasonal variation of Acinetobacter infections: 1987-1996. Nosocomial Infections Surveillance System. Clin Infect Dis 1999, 29:1133-1137.
75. Garcia-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, et al.: Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001, 33:939-946.
76. Lortholary O, Fagon JY, Buu Hoi A: et al. Colonization by Acinetobacter baumanii in intensive-care-unit patients. Infect Control Hosp Epidemiol 1998, 19:188-190.
77. Wisplinghoff H, Perbix W, Seifert H: Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: a case-control study of adult burn patients. Clin Infect Dis 1999, 28:59-66.
78. Jawad A, Seifert H, Snelling AM, et al.: Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 1998, 36:1938-1941.
79. Urban C, Segal-Maurer S, Rahal JJ: Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003, 36:1268-1274. Superb review of infections due to A. baumannii including prevalence, epidemiology, mechanisms of resistance, treatment, and infection control measures.
80. Catalano M, Quelle LS, Jeric PE, et al.: Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases. J Hosp Infect 1999, 42:27-35.
81. McDonald LC, Walker M, Carson L, et al.: Outbreak of Acinetobacter spp. bloodstream infections in a nursery associated with contaminated aerosols and air conditioners. Pediatr Infect Dis J 1998, 17:716-722.
82. Sader HS, Mendes CF, Pignatari AC, et al.: Use of macrorestriction analysis to demonstrate interhospital spread of multiresistant Acinetobacter baumannii in Sao Paulo, Brazil. Clin Infect Dis 1996, 23:631-634.
83. Wisplinghoff H, Edmond MB, Pfaller MA, et al.: Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000, 31:690-697.
84. Wu TL, Su LH, Leu HS, et al.: Molecular epidemiology of nosocomial infection associated with multi-resistant Acinetobacter baumannii by infrequent-restriction-site PCR. J Hosp Infect 2002, 51:27-32. Molecular epidemiological study of 58 nosocomial isolates of A. baumannii in Taiwan. Multidrug resistance was detected in 48 isolates (71%). Four-eight percent of these MDR strains were derived from a single clone. All 28 isolates were collected from surgical ICUs. A single strain of MDR-AB was responsible for epidemic Acinetobacter infections.
85. Go ES, Urban C, Burns J, et al.: Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994, 344:1329-1332.
86. Lortholary O, Fagon JY, Hoi AB, et al.: Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clin Infect Dis 1995, 20:790-796.
87. Fridkin SK, Steward CD, Edwards JR, et al.: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999, 29:245-252.
88. Hanberger H, Garcia-Rodriguez JA, Gobernado M, et al.: Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999, 281:67-71.
89. Mahgoub S, Ahmed J, Glatt AE: Completely resistant Acinetobacter baumannii strains. Infect Control Hosp Epidemiol 2002, 23:477-479.
90. Henwood CJ, Gatward T, Warner M, et al.: Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002, 49:479-487.
91. Koprnova J, Svetlansky I: Babel'a R., et al. Prospective study of antibacterial susceptibility, risk factors and outcome of 157 episodes of Acinetobacter baumannii bacteremia in 1999 in Slovakia. Scand J Infect Dis 2001, 33:891-895.
92. Corbella X, Ariza J, Ardanuy C, et al.: Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998, 42:793-802.
93. Levin AS: Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002, 8:144-153.
94. Wood GC, Hanes SD, Croce MA, et al.: Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002, 34:1425-1430. Retrospective study of 77 episodes of Acinetobaeter VAP in trauma patients. Fourteen patients were treated with ampicillin/sulbactam (AS); 63 received Imi-C. All isolates in the Imi-C group were susceptible to Imi; only 2 of 14 isolates in the AS group were susceptible to Imi. All isolates in both groups were susceptible to AS. Clinical outcomes were similar with AS or Imi-C (93% versus 83% improvement, respectively). Adjunctive therapy with aminoglycosides (AG) (n = 18) or ciprofloxacin (n = 1) was administered in 19 patients. Outcomes of patients receiving monotherapy or combination therapy were similar (P > 0.05). These data suggest that AS is adequate for severe pneumonia caused by A. baumannii. Although firm data are lacking, the authors recommended adding an adjunctive AG for patients treated with AS.
95. Jimenez-Mejias ME, Pachon J, Becerril B, et al.: Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997, 24:932-935.
96. Perilli M, Felici A, Oratore A, et al.: Characterization of the chromosomal cephalosporinases produced by Acinetobacter Iwoffii and Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 1996, 40:715-719.
97. Landman D, Quale JM, Mayorga D, et al.: Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 2002, 162:1515-1520. Report of a clonal outbreak of carbapenem-resistant A. baumannii (CPR-AB) and P. aeruginosa in 15 Brooklyn hospitals in 1999. Fifty-three percent of isolates of AB were resistant to carbapenems; 12% were resistant to all standard antibiotics. A single clone accounted for 62% of the samples, and was found from patients in all 15 hospitals. The rate of CPR was associated with cephalosporin use at each hospital (P = 0.004). Twenty-four percent of isolates of PA were resistant to imipenem. Three clones accounted for nearly half of the isolates, and were shared among most hospitals.
98. Rahal JJ, Urban C: Acinetobacter. Semin Resp Crit Care Med 2000, 21:341-348.
99. Jellison TK, McKinnon PS, Rybak MJ: Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001, 21:142-148.
100. Levin AS, Levy CE, Manrique AE, et al.: Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003, 21:58-62. Forty consecutive patients with nosocomial infections caused by MDR-AB were treated with ampicillin/sulbactam. The most common sites of infections were bloodstream (32.5%), pneumonia (30%), and urinary tract (15%). Cure or improvement was noted in 27 (67.5%); 6 (15%) died within 48 hours; 7 failed therapy (17.5%).
101. Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, et al.: Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002, 21:212-214.
102. Saugar JM, Alarcon T, Lopez-Hernandez S, et al.: Activities of polymyxin B and cecropin A, melittin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii. Antimicrob Agents Chemother 2002, 46:875-878.
103. Montero A, Ariza J, Corbella X, et al.: Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002, 46:1946-1952.
104. Wolff M, Joly-Guillou ML, Farinotti R, et al.: In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 1999, 43:1406-1411.
105. Muder RR, Harris AP, Muller S, et al.: Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996, 22:508-512.
106. Sanyal SC, Mokaddas EM: The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999, 11:28-33.
107. Dignani M, Grazziutti M, Anaissie E: Stenotrophomonas maltophilia infections. Semin Resp Crit Care Med 2003, 24:89-98. Excellent review of Stenotrophomonas maltophilia including epidemiology, transmission, risk factors for colonization and infection, clinical features, treatment, and prevention.
108. Spencer RC: The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995, 30(suppl):453-464.
109. Elting LS, Khardori N, Bodey GP, et al.: Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 1990, 11:134-138.
110. Hanes SD, Demirkan K, Tolley E, et al.: Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002, 35:228-235. Retrospective study, assessed risk factors for late onset pneumonia due to Stenotrophomonas maltophilia in critically ill trauma patients. By multivariate analysis, a single episodes of S. maltophilia pneumonia was associated with the following risk factors: prior cefepime use and tracheostomy. Among patients with multiple pneumonia episodes, risk factors included pulmonary contusion and higher Injury Severity Score. Inadequate empirical antibiotic therapy was associated with a higher mortality rate.
111. Vartivarian S, Anaissie E, Bodey G, et al.: A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994, 38:624-627.
112. Cosgrove SE, Kaye KS, Eliopoulous GM, et al.: Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002, 162:185-190.
113. Cosgrove SE, Carmeli Y: The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003, 36:1433-1437. This article evaluates health and economic impact of colonization and infection with resistant organisms while addressing the limitations of these types of studies.
114. Kollef MH: An empirical approach to the treatment of multidrug-resistant ventilator-associated pneumonia. Clin Infect Dis 2003, 36:1119-1121.
115. Ibrahim EH, Ward S, Sherman G, et al.: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001, 29:1109-1115.
116. Dennesen PJ, van der Ven AJ, Kessels AG, et al.: Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001, 163:1371-1375.
117. Paterson DL, Rice LB: Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003, 36:1006-1012. Excellent review of strategies to combat or limit antimicrobial resistance in ICUs. Discusses in detail three strategies including (1) discontinuing or streamlining therapy once culture results are available; (2) selected withdrawal of certain antibiotic classes (most notably, third-generation cephalosporins) from the antibiotic armamentarium; and (3) antibiotic cycling.
118. Harris AD, Samore MH, Lipsitch M, et al. Control group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 2003, 34;1558-1562. The authors emphasize the importance of selected appropriate control groups when evaluating the impact of prior antimicrobial use on antibiotic resistance. Risk factors for imipenem-resistant P. aeruginosa (IRPA), vancomycin-resistant enterococci (VRE), and ampicillin-sulbactam-resistant Escherichia coli (ASREC) were examined. Prior antibiotic use (within 7 days) was documented. Case patients had clinical cultures positive for antimicrobial-resistant organisms. Two control groups were used. The first control group included patients with clinical cultures positive for antimicrobial-susceptible isolates. The second group comprised randomly selected controls. Inclusion of patients with antibiotic-susceptible isolates as controls introduces a bias, and may overrate the magnitude or risk and may even falsely identify risk factors.